The Rheumatoid Arthritis (RA) market is expanding due to the growing prevalence of this chronic autoimmune disease, which affects joints and can lead to disability if untreated. The market includes a range of treatments, from non-steroidal anti-inflammatory drugs (NSAIDs) to advanced biologics and disease-modifying antirheumatic drugs (DMARDs). Recent research focuses on precision medicine, aiming to tailor treatments to individual genetic profiles, improving efficacy and reducing side effects. As patient awareness and early diagnosis increase, the demand for innovative RA treatments continues to rise. https://www.analytica.global/research/rheumatoid-arthritis-market #RheumatoidArthritis #AutoimmuneDisease #Biologics #PrecisionMedicine #ChronicPain